Novartis Benefits From Lack of Generic Challenge

REPLAY VIDEO
Your next video will start in
Pause

Recommended Videos

  • Info

  • Comments

April 24 (Bloomberg) -- Bloomberg's Jonathan Ferro reports that Novartis AG saw first-quarter profit rise 7 percent as a competitor's generic version of the company’s second-best-selling medicine failed to reach the market. He speaks on Bloomberg Television's "On The Move."

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change